Ingevity CORP Form 4 insider transactions

Ingevity Corp's President and CEO, David H. Li, reported the acquisition of 38,179 restricted stock units and additional common stock through an employee stock purchase plan.

Ingevity's EVP and Chief Financial Officer, Mary Dean Hall, acquired common stock through performance share unit vesting and subsequently disposed of shares for tax obligations.

Ingevity's SVP and President of Performance Chemicals, Richard Allen White JR, increased his beneficial ownership through performance share unit vesting and subsequent tax-related share withholding.

Ingevity's SVP of Finance and CAO, Phillip John Platt, reported the acquisition of common stock from performance-based awards and subsequent sale for tax obligations.

Ingevity's SVP, General Counsel & Secretary, Ryan C. Fisher, reported the acquisition of shares from vested performance awards and the disposition of shares for tax withholding.

Ingevity's SVP of Operations, Clarence Reid Clontz Jr., reported acquiring common stock through PSU settlement and an employee stock purchase plan, alongside a disposition for tax withholding.

Ingevity Corp Director Francis David Segal acquired 396 shares of common stock through vested deferred stock units as part of his compensation plan.

Ingevity Corp. Director J. Kevin Willis acquired 479 shares of common stock through vested deferred stock units, increasing his direct beneficial ownership to 8,779 shares.

Ingevity Director Luis Fernandez-Moreno reported a future tax withholding of 6,004 shares and a forfeiture of 11,123 RSUs related to his prior Interim CEO role.

Ingevity Director Francis David Segal acquired 414 shares of common stock through deferred stock units, increasing his direct beneficial ownership to 5,655 shares.

Ingevity Corp Director J. Kevin Willis is scheduled to acquire 506 shares of common stock at $54.44 per share through vested deferred stock units on October 1, 2025.

Ingevity Corp's SVP of Finance and CAO, Phillip J. Platt, disposed of 1,444 common shares to cover tax withholding obligations from vested 2024 RSUs.

Ingevity Corporation's SVP, General Counsel & Secretary, Ryan C. Fisher, reported the disposition of 169 common shares to cover tax liabilities related to the vesting of restricted stock units.

Ingevity Corp Director J. Kevin Willis acquired 620 shares of common stock on July 1, 2025, through the vesting of deferred stock units received in lieu of director fees.

Ingevity Corp Director Francis David Segal acquired 507 shares of common stock on July 1, 2025, through the vesting of deferred stock units received in lieu of director fees.

Director Jean Blackwell reports the grant of restricted stock units and details holdings including those held in a revocable trust.

Director Luis Fernandez-Moreno reports acquisition of 4,057 restricted stock units in Ingevity Corp, vesting on May 1, 2026, along with an updated power of attorney.

Director Frederick J. Lynch reported acquiring 4,057 shares of Ingevity Corp common stock through a grant of restricted stock units.

Director Daniel F. Sansone reported the acquisition of 4,057 shares of common stock via a restricted stock unit grant and the disposal of 6,827 shares held indirectly through a family trust.

Director Diane H. Gulyas reports the acquisition of restricted stock units and a disposition of shares held in trust.

Director Karen G. Narwold reports the acquisition of 4,057 deferred stock units (DSUs) in Ingevity Corp, vesting on May 1, 2026, and also grants a limited power of attorney for SEC reporting purposes.

Director Benjamin G. Wright reports acquisition of 4,057 deferred stock units and disposal of 10,044 common stock shares.

Director Bruce D. Hoechner received 4,057 deferred stock units from Ingevity Corp on May 1, 2025, according to a Form 4 filing.

Director J. Kevin Willis reports acquisition of deferred stock units and vested DSUs, along with a power of attorney update.

Director Francis David Segal reports acquisition of deferred stock units and vested deferred stock units in Ingevity Corp.

David H. Li, President & CEO of Ingevity Corp, files an amendment to a previous Form 4 to correct the number of employee stock options granted.

David H. Li, President & CEO of Ingevity Corp, reports the acquisition of common stock and stock options.

Director J. Kevin Willis acquired 580 shares of Ingevity Corp common stock through vested deferred stock units (DSUs) at a price of $38.85 per share.

Ryan C. Fisher, SVP, Gen. Counsel & Secretary of Ingevity Corp, reports disposition of shares to cover tax obligations related to vested RSUs.

EVP and CFO of Ingevity Corp, Mary Dean Hall, reports acquisition and disposal of common stock related to vesting of restricted stock units and tax obligations.